ABBVIE

The FDA has awarded fast track designation to UB-VV111 for treating relapsed/refractory large B-cell lymphoma and chronic lymphocytic leukemia after at least two prior therapies.

AbbVie has submitted a Biologics License Application to the FDA for pivekimab sunirine, a CD123-targeting antibody-drug conjugate designed to treat Blastic Plasmacytoid Dendritic Cell Neoplasm.

AbbVie announced it will launch its ovarian cancer drug Elahere in the UK at a list price matching that in the U.S., following President Trump's most-favored-nation pricing policy demands.

Moonlake Immunotherapeutics' experimental drug sonelokimab delivered mixed results in two late-stage hidradenitis suppurativa trials, with one study meeting statistical significance but falling short of investor expectations.

Quebec's RAMQ has added QULIPTA (atogepant) to its formulary for both chronic and episodic migraine prevention, expanding access to this oral CGRP receptor antagonist.

Sanofi commits an additional $625 million to its corporate venture arm, bringing total assets under management to over $1.4 billion for strategic biotech investments.

Amneal Pharmaceuticals received FDA approval for its generic version of bimatoprost ophthalmic solution 0.01%, a prostaglandin analog used to reduce elevated intraocular pressure in glaucoma patients.

Allergan Aesthetics announced the rollout of SKINVIVE by JUVÉDERM® in 35 additional markets, bringing the total to 57 global launches in 2025.

Myricx Bio has appointed Mohit Rawat as CEO, bringing extensive biopharma experience from Fusion Pharmaceuticals, which was acquired by AstraZeneca for $2.4 billion in 2024.

Alnylam Pharmaceuticals has joined the Alliance for Genomic Discovery as the ninth member, gaining access to a comprehensive clinical genomic database containing 250,000 whole-genomes to accelerate RNA interference therapeutic development.